{"organizations": [], "uuid": "144fb0bc5dcfabd70e5fd9e05c99d035d8902eab", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-insmed-reports-q1-loss-per-share-0/brief-insmed-reports-q1-loss-per-share-0-89-idUSASC09YYD", "country": "US", "domain_rank": 408, "title": "BRIEF-Insmed Reports Q1 Loss Per Share $0.89", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T14:36:00.000+03:00", "replies_count": 0, "uuid": "144fb0bc5dcfabd70e5fd9e05c99d035d8902eab"}, "author": "", "url": "https://www.reuters.com/article/brief-insmed-reports-q1-loss-per-share-0/brief-insmed-reports-q1-loss-per-share-0-89-idUSASC09YYD", "ord_in_thread": 0, "title": "BRIEF-Insmed Reports Q1 Loss Per Share $0.89", "locations": [], "entities": {"persons": [], "locations": [{"name": "insmed", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "amikacin liposome", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "insmed inc", "sentiment": "none"}, {"name": "mac", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2, 2018 / 11:38 AM / Updated 4 minutes ago BRIEF-Insmed Reports Q1 Loss Per Share $0.89 Reuters Staff\nMay 2 (Reuters) - Insmed Inc:\n* INSMED REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE * Q1 LOSS PER SHARE $0.89\n* Q1 EARNINGS PER SHARE VIEW $-0.98 â€” THOMSON REUTERS I/B/E/S\n* PREPARING FOR POTENTIAL PRODUCT LAUNCH OF ALIS IN 4Q 2018\n* SUBMITTED NDA TO FDA FOR AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) IN NTM LUNG DISEASE CAUSED BY MAC; ANTICIPATES PRIORITY REVIEW\n* AS OF MARCH 31, 2018, INSMED HAD CASH AND CASH EQUIVALENTS OF $686.6 MILLION Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-02T14:36:00.000+03:00", "crawled": "2018-05-02T15:30:49.010+03:00", "highlightTitle": ""}